Interleukin-28 and hepatitis C virus genotype-4: treatment-induced clearance and liver fibrosis.

ABSTRACT:

Aim

To investigate the association between interleukin-28B (IL28B) genotype and response to treatment and hepatic fibrosis in patients with hepatitis C virus (HCV) genotype 4.

Methods

Two hundred and one HCV-genotype 4 patients were included. All patients were treated with Peginterferon alph2a/Ribavirin for 48 wk. End of treatment response (ETR) was defined as loss of detectable serum HCV RNA at the end of treatment. Sustained viral response (SVR) was defined as loss of detectable serum HCV RNA at the end of 24 wk follow up. Genotyping of IL28B rs12979860 was performed using the TaqMan assay. We used logistic regression to estimate the adjusted odds ratio (aOR) and 95%CI.

Results

The study included 201 HCV-genotype 4 patients. The majority of patients were men (89.6%)

SUBMITTER: Derbala M 

PROVIDER: S-EPMC3531686 | biostudies-literature | 2012 Dec

REPOSITORIES: biostudies-literature